Business Context and Reporting Period
Company: CalciMedica, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 6, 2025
Reporting Period: Single event date (November 6, 2025)
Business Context: The Company is an emerging growth company incorporated in Delaware, with principal executive offices in La Jolla, California. Its common stock trades on The Nasdaq Capital Market under the symbol "CALC".
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on a capital market transaction.
Material Changes
The primary material event reported is the expansion of the Company's At-The-Market (ATM) offering program:
- Previous Offering Limit: $4,450,000 (under the August 11, 2023 agreement with H.C. Wainwright & Co.).
- New Offering Limit: $9,700,000.
- Incremental Capacity: The increase adds $5,250,000 to the maximum aggregate offering price available for sale.
- Instrument: The change was effected via a Prospectus Supplement filed with the SEC on November 6, 2025.
Guidance, Outlook, and Risks
Management Commentary: The filing contains no forward-looking guidance, earnings outlook, or specific management commentary regarding operational strategy beyond the execution of the capital raise mechanism.
Risks and Contingencies: The filing does not explicitly detail new risks or contingencies. However, the expansion of the ATM program implies a continued need for liquidity and potential dilution to existing shareholders as shares are sold into the market.
Unusual Items: None reported in this filing.
Investor Verification Checklist
- Verify the current market price of CALC to assess the potential dilution impact of the additional $5.25 million in share issuance capacity.
- Review the full Prospectus Supplement (referenced in the filing) for specific terms regarding the sales agreement with H.C. Wainwright & Co.
- Check recent 10-Q or 10-K filings for the Company's current cash position to understand the urgency of this capital raise.
- Confirm the total number of shares previously sold under the original $4.45 million limit to gauge the remaining capacity under the new $9.7 million limit.